Therapeutic Human Polyclonals Inc.
Records under this name other than the patents Therapeutic Human Polyclonals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 6 of 6 · Back to Therapeutic Human Polyclonals Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,354,568 | Suppression of B-cell apoptosis in transgenic animals expressing humanized immunoglobulin Term ended Term ended Aug 2, 2026 · USPTO record | Term ended | Term ended Aug 2, 2026 | USPTO record |
| US 7,585,668 | Humanized immunoglobulin loci Term ended Term ended Jan 20, 2026 · USPTO record | Term ended | Term ended Jan 20, 2026 | USPTO record |
| US 8,410,333 | Humanized immunoglobulin loci Term ended Term ended Jul 15, 2024 · USPTO record | Term ended | Term ended Jul 15, 2024 | USPTO record |
| US RE47,131 | Humanized immunoglobulin loci Term ended Term ended Jul 15, 2024 · USPTO record | Term ended | Term ended Jul 15, 2024 | USPTO record |
| US 7,129,084 | Production of humanized antibodies in transgenic animals Term ended Term ended Sep 24, 2021 · USPTO record | Term ended | Term ended Sep 24, 2021 | USPTO record |
| US 8,652,842 | Humanized immunoglobulin loci Surrendered on reissue Surrendered on reissue Nov 20, 2018 · USPTO record | Surrendered on reissue | Surrendered on reissue Nov 20, 2018 | USPTO record |